Resiquimod Hydrogel-based

What is Resiquimod Hydrogel-based?

Resiquimod hydrogel-based (TransCon TLR7/8 Agonist) is a sustained-release hydrogel formulation of resiquimod, an imidazoquinolinamine that binds Toll-like receptors 7 and 8 on dendritic cells, macrophages and B-lymphocytes. Intratumoral administration activates TLR signaling, NF-kB-dependent cytokine production and Th1 and cytotoxic T-lymphocyte responses. It is being studied in solid tumors, including ovarian, cervical, melanoma, lung and HER2-positive breast cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Small molecule

Targets

Toll-like receptor 7 (TLR7), Toll-like receptor 8 (TLR8)

Mechanism

Immune activation, directed at Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8)

Pathways

TLR signaling pathway, NF-kB activation, interferon-alpha production, Th1 immune response, cytotoxic T-lymphocyte activation

Therapy area

Oncology

Developer

Ascendis Pharma Oncology Division A/S (ASND)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

2L+ Cervical CancerAdvanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorNeoadjuvant MelanomaNeoadjuvant Non-Small Cell Lung CancerPlatinum-resistant Ovarian CancerPost Anti-PD-(L)1 Non-Small Cell Lung CancerPost Anti-PD-(L)1 Small Cell Lung CancerPost Anti-PD-1 MelanomaSecond or Third Line (2L/3L) Cervical CancerThird Line or Later (3L+) HER2+ Breast Cancer

Other drugs acting on TLR7 / TLR8

More from Ascendis Pharma Oncology Division

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05081609

Updated Oct 11, 2026. Something wrong or missing? Report it on the ASND page.